Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Conditions

Melanoma 49Breast Neoplasms 47Neoplasms 39Leukemia, Lymphocytic, Chronic, B-Cell 37Carcinoma, Non-Small-Cell Lung 36Neoplasm Metastasis 29Lymphoma, Large B-Cell, Diffuse 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Brain Neoplasms 24Lymphoma, Follicular 23Lung Neoplasms 23Colonic Neoplasms 23Rectal Neoplasms 22Carcinoma, Renal Cell 22Lymphoma, Non-Hodgkin 21Prostatic Neoplasms 20Glioblastoma 20Leukemia, Myeloid, Acute 19Kidney Neoplasms 19Pancreatic Neoplasms 18Lymphoma, B-Cell, Marginal Zone 18Lymphoma, Mantle-Cell 17Gliosarcoma 17Burkitt Lymphoma 17Sarcoma 16Multiple Myeloma 16Waldenstrom Macroglobulinemia 15Ovarian Neoplasms 15Esophageal Neoplasms 15Lymphoma 14

Interventions

infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × NIH × Oncogenic osteomalacia × Clear all
NCT03510455 2021-04-08

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 28 charts

Oncogenic osteomalacia, Hypophosphatemia

NCT01748812 2018-07-05

Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled

Oncogenic osteomalacia, Osteomalacia, Rickets, Hypophosphatemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡